TRVI
What one share of Trevi Therapeutics holds
Pharmaceutical Preparations
We are a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC.
Trevi Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.34 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.36 |
| Cash and investments | $2.24 |
| Book value | $2.26 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | — | −$58.45 | $0.36 | −$42.15 | — | −$249.64 |
| 2019 | — | −$2.28 | $0.00 | −$1.97 | — | $3.06 |
| 2020 | — | −$1.81 | $0.00 | −$1.61 | — | $1.47 |
| 2021 | — | −$1.49 | — | −$1.27 | — | $0.60 |
| 2022 | — | −$0.45 | $0.00 | −$0.44 | — | $1.79 |
| 2023 | — | −$0.29 | $0.00 | −$0.32 | — | $1.21 |
| 2024 | — | −$0.47 | $0.00 | −$0.38 | — | $1.06 |
| 2025 | — | −$0.32 | $0.00 | −$0.31 | — | $1.43 |